PL2807153T3 - Związki heterocykliczne i sposoby ich zastosowania - Google Patents

Związki heterocykliczne i sposoby ich zastosowania

Info

Publication number
PL2807153T3
PL2807153T3 PL13741446T PL13741446T PL2807153T3 PL 2807153 T3 PL2807153 T3 PL 2807153T3 PL 13741446 T PL13741446 T PL 13741446T PL 13741446 T PL13741446 T PL 13741446T PL 2807153 T3 PL2807153 T3 PL 2807153T3
Authority
PL
Poland
Prior art keywords
methods
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
PL13741446T
Other languages
English (en)
Inventor
Thomas David Mccarthy
Alan Naylor
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012900286A external-priority patent/AU2012900286A0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2807153T3 publication Critical patent/PL2807153T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL13741446T 2012-01-25 2013-01-25 Związki heterocykliczne i sposoby ich zastosowania PL2807153T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012900286A AU2012900286A0 (en) 2012-01-25 "Methods of treatment or prophylaxis"
EP13741446.2A EP2807153B1 (en) 2012-01-25 2013-01-25 Heterocyclic compounds and methods for their use
PCT/AU2013/000061 WO2013110134A1 (en) 2012-01-25 2013-01-25 Heterocyclic compounds and methods for their use

Publications (1)

Publication Number Publication Date
PL2807153T3 true PL2807153T3 (pl) 2020-09-07

Family

ID=48872832

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13741446T PL2807153T3 (pl) 2012-01-25 2013-01-25 Związki heterocykliczne i sposoby ich zastosowania

Country Status (12)

Country Link
US (2) US20150011565A1 (pl)
EP (1) EP2807153B1 (pl)
JP (2) JP6258867B2 (pl)
CN (1) CN104470903B (pl)
AU (1) AU2013202973C9 (pl)
CA (1) CA2861231C (pl)
ES (1) ES2798289T3 (pl)
NZ (1) NZ627560A (pl)
PL (1) PL2807153T3 (pl)
PT (1) PT2807153T (pl)
WO (1) WO2013110134A1 (pl)
ZA (1) ZA201405255B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
PL2800738T3 (pl) 2012-01-06 2020-10-19 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
US20150011565A1 (en) * 2012-01-25 2015-01-08 Spinifex Pharmaceuticals Pty Ltd Heterocyclic Compounds and Methods For Their Use
PL3019477T3 (pl) 2013-07-08 2021-11-22 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
WO2015063709A1 (en) * 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
EP3245198B1 (en) * 2015-01-13 2020-03-11 Novartis AG Pyrrolidine derivatives as angiotensin ii type 2 antagonists
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
TWI693221B (zh) 2015-01-15 2020-05-11 瑞士商愛杜西亞製藥有限公司 作為cxcr3受體調節劑之羥烷基六氫吡衍生物
EP3268356B1 (en) 2015-03-12 2021-08-25 Novartis Ag Heterocyclic compounds and methods for their use
CN105503787A (zh) * 2015-12-31 2016-04-20 阜阳欣奕华材料科技有限公司 一种索非布韦中间体的纯化方法
WO2019040105A2 (en) * 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
EP3724178B1 (en) 2017-12-15 2024-05-01 Inthera Bioscience AG 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
EP4168014A1 (en) 2020-06-19 2023-04-26 Inthera Bioscience AG Oxopiperazine derivatives for the treatment of cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400511A (en) * 1982-05-07 1983-08-23 American Home Products Corporation 2-Substituted octahydropyrrolo(1,2-A)-pyrazine-3-carboxylic acids
EP0398720A3 (en) * 1989-05-18 1991-07-03 Glaxo Group Limited Piperazine derivatives
WO1992020661A1 (en) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
US5348955A (en) * 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
EP0926138A4 (en) * 1996-08-23 2006-04-12 Kowa Co DIAMIDE COMPOUNDS AND MEDICAMENTS CONTAINING SAME
KR100640672B1 (ko) * 1997-06-17 2006-11-02 파마코페이아 드럭 디스커버리, 인크. 파르네실 단백질 트랜스퍼라제의 억제에 유용한 벤즈피리도 사이클로헵탄 화합물 및 이를 포함하는 약제학적 조성물
US5968938A (en) * 1997-06-18 1999-10-19 Merck & Co., Inc. Piperazine oxytocin receptor antagonists
US6951862B2 (en) * 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US20060084660A1 (en) * 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
AU2003259131A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
DE10309005A1 (de) * 2003-03-01 2004-09-09 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen, die Dipetidyl Peptidase (DPPIV) und Neurale Endopeptidase (NEP) inhibieren
EP1745042A4 (en) * 2004-04-09 2010-07-14 Neuromed Pharmaceuticals Ltd DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
WO2006066361A1 (en) * 2004-12-24 2006-06-29 The University Of Queensland Method of treatment or prophylaxis
WO2006086609A2 (en) * 2005-02-10 2006-08-17 Axys Pharmaceuticals, Inc. Inhibitors of tryptase
US20070049578A1 (en) * 2005-08-24 2007-03-01 Astrazeneca Ab Cinnamamide compounds as metabotropic glutamate receptor antagonists
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
AU2007229322B2 (en) 2006-03-20 2012-04-05 Novartis Ag Method of treatment or prophylaxis inflammatory pain
US8362021B2 (en) * 2006-05-11 2013-01-29 Zalicus Pharmaceuticals Ltd. Method for increasing the bioavailability of benzhydryl piperazine containing compounds
JP2008031064A (ja) * 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体
JP2009007341A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
US7960406B2 (en) 2008-06-25 2011-06-14 Bristol-Myers Squibb Company Diketo substituted pyrrolo[2,3-c] pyridines
ES2560327T3 (es) 2010-01-19 2016-02-18 Novartis Ag Métodos y composiciones para una velocidad de conducción nerviosa mejorada
PL2800738T3 (pl) 2012-01-06 2020-10-19 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
WO2013110135A1 (en) 2012-01-25 2013-08-01 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
US20150011565A1 (en) * 2012-01-25 2015-01-08 Spinifex Pharmaceuticals Pty Ltd Heterocyclic Compounds and Methods For Their Use

Also Published As

Publication number Publication date
US20150011565A1 (en) 2015-01-08
US20160257656A1 (en) 2016-09-08
AU2013202973C1 (en) 2016-11-24
EP2807153A1 (en) 2014-12-03
ZA201405255B (en) 2019-04-24
AU2013202973C9 (en) 2016-12-22
JP6258867B2 (ja) 2018-01-10
PT2807153T (pt) 2020-06-18
CN104470903B (zh) 2017-02-22
WO2013110134A1 (en) 2013-08-01
HK1201533A1 (en) 2015-09-04
AU2013202973B9 (en) 2016-11-24
CA2861231A1 (en) 2013-08-01
JP2015504900A (ja) 2015-02-16
EP2807153B1 (en) 2020-03-25
AU2013202973B2 (en) 2016-06-02
EP2807153A4 (en) 2015-06-10
JP2018076297A (ja) 2018-05-17
CA2861231C (en) 2021-04-13
NZ627560A (en) 2016-08-26
CN104470903A (zh) 2015-03-25
US9708275B2 (en) 2017-07-18
ES2798289T3 (es) 2020-12-10

Similar Documents

Publication Publication Date Title
ZA201405253B (en) Heterocyclic compounds and methods for their use
ZA201401434B (en) Heterocyclic compounds and uses thereof
IL230536A0 (en) Heterocyclic compounds and their uses
EP2678016A4 (en) HETEROCYCLIC COMPOUNDS AND USES THEREOF
SG11201504049VA (en) Compounds and their methods of use
PT2920149T (pt) Compostos de 3-aminocicloalquil como inibidores de ror-gama-t e utilizações dos mesmos
ZA201405257B (en) Heterocyclic compounds and methods for their use
ZA201405255B (en) Heterocyclic compounds and methods for their use
AP2015008591A0 (en) Heterocyclic compounds
EP2832734A4 (en) HETEROCYCLIC COMPOUND
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
HUE062842T2 (hu) Új heterociklusos származékok és alkalmazásaik
GB201111705D0 (en) Compounds and their use
AP3611A (en) Heterocyclic compounds and their uses
EP2782571A4 (en) HETEROCYCLIC COMPOUNDS AND USES THEREOF
PL2882708T3 (pl) Nowe związki i ich zastosowania
GB201213726D0 (en) Novel compounds and their use
GB201206973D0 (en) New compounds and uses
GB201207075D0 (en) New compounds and uses
GB201206055D0 (en) New compounds and uses
GB201214749D0 (en) Compounds and their uses
GB201202400D0 (en) Nitrogen-containing heterocyclic compounds
GB201104444D0 (en) Compounds and their use